Search

Search Results
Results 83321 - 83330 of 85911 for ADD
  • Exploring the history and potential of CAR-T cell therapies
    White Paper - 1 Feb 2024
    This article explores the history behind CAR-T cell therapies and what the future holds for this life-saving therapeutic.
  • Successful hepatocyte handling: What do you need to know?
    White Paper - 1 Feb 2024
    This article explores hepatocyte handling and the top tips you need to know to do it successfully.
  • Temodal
    Drug - 29 Jan 2024
    Consumer Medicine Information (CMI) about Temodal intended for persons living in Australia.
  • Noriday
    Drug - 28 Jan 2024
    Consumer Medicine Information (CMI) about Noriday intended for persons living in Australia.
  • Rhinocort Aqueous
    Drug - 28 Jan 2024
    Consumer Medicine Information (CMI) about Rhinocort Aqueous intended for persons living in Australia.
  • Budamax Aqueous
    Drug - 28 Jan 2024
    Consumer Medicine Information (CMI) about Budamax Aqueous intended for persons living in Australia.
  • Incruse Ellipta
    Drug - 28 Jan 2024
    Consumer Medicine Information (CMI) about Incruse Ellipta intended for persons living in Australia.
  • Axotide Accuhaler and MDI
    Drug - 28 Jan 2024
    Consumer Medicine Information (CMI) about Axotide Accuhaler and MDI intended for persons living in Australia.
  • Olamlo HCT
    Drug - 28 Jan 2024
    Consumer Medicine Information (CMI) about Olamlo HCT (Olmesartan medoxomil, amlodipine and hydrochlorothiazide) intended for persons living in Australia.
  • Characterize viral vectors easily
    White Paper - 11 Jan 2024
    In this article, Bio-Techne explains how to achieve efficient viral vector characterization all the way to GMP release.

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback